Author's response to reviews

Title: Antifungal Prophylaxis in Chemotherapy-Associated Neutropenia: a Retrospective, Observational Study

Authors:

Amy Riedel (amyoriedel@yahoo.com)
Lan Choe (chaulan@hotmail.com)
John Inciardi (inciardij@pharmacy.ucsf.edu)
Courtney Yuen (courtney.yuen@ucsfmedctr.org)
Thomas Martin (tmartin@medicine.ucsf.edu)
B. Joseph Guglielmo (guglielmoj@pharmacy.ucsf.edu)

Version: 3 Date: 29 March 2007

Author's response to reviews:

Dear Editors,

Thank you for accepting, in principle, our manuscript Antifungal Prophylaxis in Chemotherapy-Associated Neutropenia: a Retrospective, Observational Study. All of the requested formatting changes have been made. Please find below our responses to the reviewers' comments.

Sincerely,

Amy Riedel, Pharm.D.

Bassetti:

1. The most important limitation of the paper is that the use of voriconazole in febrile neutropenia has not been approved by FDA, following the results of the Walsh et al study published in NEJM

   a. Although we do not believe the off-label use of voriconazole is a limitation to our study, we did address the rationale for the off-label use of voriconazole in the Background section of the manuscript.

Bedogni

2. Report the correct "minus" sign in confidence intervals.

   a. The manuscript was corrected with the appropriate minus signs in the confidence intervals

3. I suggest to change the main text as reported in 9b of the authors' replies

   (9b: Similarly, dichotomous variables (infection, renal toxicity, hepatic toxicity) were analyzed using random effects logistic regression. These models controlled for the number of hospitalizations and include fixed effects for each medication and for each period.)

   a. This information is included in the statistical analysis section of the manuscript.